版本:
中国

BRIEF-Portola Pharmaceuticals interim data from a phase 2A study evaluating Cerdulatinib

June 15 Portola Pharmaceuticals Inc

* Interim data from a phase 2A study evaluating Cerdulatinib in patients with relapsed/refractory B-cell malignancies

* Interim results demonstrated evidence of clinical activity in patients with relapsed/refractory (R/R) B-cell malignancies

* A complete response was seen in first R/R peripheral T cell lymphoma (PTCL) patient evaluated in study

* Results also showed that Cerdulatinib was generally well-tolerated in the heavily pre-treated patients

* Anticipate an update on ongoing study on Cerdulatinib and a decision regarding future development by end of 2017

* Reduction in doseage resulted in an improved PK and safety profile without compromising clinical activity Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐